KRROHIGH SIGNALRISK10-K

KRRO experienced failed clinical trial results for their lead candidate KRRO-110, triggering organizational streamlining and a paused collaboration with Novo Nordisk, while burning through 68% of their equity base.

The language changes reveal that KRRO's Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD has failed, marking a critical setback for this early-stage biotech company. The paused Novo Nordisk collaboration and organizational restructuring indicate management is scrambling to preserve capital and reassess strategy after this clinical failure.

Comparing 2026-03-12 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

Despite revenue increasing 182% to $6.4M, KRRO's financial position deteriorated dramatically with net losses expanding 40% to $117.3M and stockholders' equity collapsing 68% to just $51.4M. Cash burned down 61% to $21.8M while operating cash flow worsened to -$78.6M, creating an urgent funding crisis. The 97% reduction in capital expenditures to $518K signals severe cost-cutting measures as the company preserves remaining cash following clinical trial failures.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+181.5%
$2.3M→$6.4M

Strong top-line growth of 181.5% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
-97.1%
$17.9M→$518K

Capex reduced 97.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-67.9%
$160.4M→$51.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-60.8%
$55.6M→$21.8M

Cash declined 60.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
-49.8%
$226.2M→$113.5M

Total assets contracted 49.8% — asset sales, write-downs, or balance sheet optimization underway.

Net Income
P&L
-40.3%
-$83.6M→-$117.3M

Net income declined 40.3% — review whether driven by operations, interest costs, or non-recurring items.

Current Assets
Balance Sheet
-37.4%
$131.5M→$82.4M

Current assets declined 37.4% — monitor working capital adequacy and short-term liquidity.

Operating Income
P&L
-32.6%
-$91.9M→-$121.9M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-30.8%
-$60.1M→-$78.6M

Operating cash flow fell 30.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
+25.8%
$764K→$961K

Interest costs rose 25.8% — monitor debt levels and coverage ratio in rising rate environment.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-18
ADDED
In this Annual Report, when we refer to our leads or lead candidates, we are referring to our oligonucleotides that we are researching for potential nomination as a development candidate.
When we refer to our development candidates, we generally mean an oligonucleotide lead candidate that we have nominated for clinical development.
If preclinical studies or clinical trials of any lead candidates or development candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results (such as we experienced in the Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD), we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such development candidates.
We may not realize the anticipated benefits of our organizational streamlining and workforce reduction..
We have yet to successfully complete clinical development of any development candidate, and any favorable results we have may not be predictive of results that may be observed in later preclinical studies or clinical trials, such as our experience in the Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD.
+7 more — sign up free →
REMOVED
We have dosed very few participants in our Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, or AATD, and not received any clinical trial results for any of our proposed delivery methods or RNA editing approaches in clinical trials.
Any favorable results we may have may not be predictive of results that may be observed in later preclinical studies or clinical trials.
If preclinical studies or clinical trials of any product candidates we may identify and develop fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.
If we experience delays or difficulties in the enrollment of patients in clinical trials, or other delays in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
Our business may be impacted by macroeconomic conditions, including fears concerning the financial services industry, inflation, rising interest rates and volatile market conditions, and other uncertainties beyond our control.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →